Society of Nuclear Medicine and Molecular Imaging (SNMMI)

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), formerly the Society of Nuclear Medicine, is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging (PET and SPECT). The bulk of nuclear imaging exams relate to oncology, about a third to cardiac imaging and the rest for a variety of protocols, including imaging inflammation and beta-amyloid plaques that cause Alzheimer's disease.

Nuclear imaging groups share new flurpiridaz guideline
Several groups collaborated on the document, which is designed to help clinicians provide high-quality, consistent care when using flurpiridaz during cardiac PET imaging exams.
How to score accreditation for a radiotherapy theranostics program
Wes Folds, a PET specialist with the Intersocietal Accreditation Commission, discusses a new nuclear offering from IAC.
Policy reforms in Washington that will impact nuclear imaging
SNMMI President Cathy Cutler, PhD, explains some of the key policy initiatives the society is pursuing to help support the field of nuclear medicine.
U.S. moves closer to establishing domestic supply of Mo-99 for nuclear imaging
Society of Nuclear Medicine and Molecular Imaging President, Cathy Cutler, explains the long road to jump-starting a new U.S. domestic supply of imaging isotopes.
SNMMI unveils Image of the Year
This year the Henry N. Wagner Jr., Image of the Year is actually a group of images displaying the efficacy of a 68Ga-DOTA-5G and 177Lu-DOTA-ABM-5G theranostic pairing that improves the detection and treatment of metastatic pancreatic cancer.

Imaging industry advocate slams feds’ failure to address PET coverage gap in recent ruling

The Society for Nuclear Medicine & Molecular Imaging expressed "strong opposition" following CMS' decision, arguing there is no evidence to support limiting pay for such scans.

FDA approves new radioligand therapy for PSMA positive metastatic prostate cancer

In clinical trials, the therapy reduced patients' risk of death by 38%, along with significantly decreasing disease progression.

FDA approves new therapy, complementary imaging agent for treating metastatic prostate cancer

Provider advocates praised the decision, calling it “one of the greatest success stories in nuclear medicine history.”

SNMMI selects first Radiopharmaceutical Therapy Centers of Excellence

The Society of Nuclear Medicine and Molecular Imaging's program was established to ensure that institutions adhere to the strict regulatory training, qualification and performance standards necessary to safely deliver radiopharmaceutical therapies.

Radiology leaders speak out in support of Ukraine

In the wake of Russia’s invasion of Ukraine, leaders in the radiology community are speaking out and publicly denouncing the aggressions.

Several medical imaging societies ask to be involved in Congressional Medicare reform efforts

Numerous medical imaging societies, including the ACR, signed onto a letter dated Feb. 25 that was sent to members of Congress requesting collaboration on reforms to the Medicare physician payment system.

Prominent imaging society advocates for 5 changes following CMS amyloid PET payment decision

SNMMI is fighting for expanded coverage for amyloid PET, including broadening accepted sites of service, among other changes.

Medical isotope shortage looms as 'unplanned' outage halts Mo-99, Lu-177 production

The root cause of the problem has not yet been discovered, halting isotope production for an undisclosed amount of time, according to SNMMI.

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Nuclear imaging groups share new flurpiridaz guideline

How to score accreditation for a radiotherapy theranostics program

Policy reforms in Washington that will impact nuclear imaging

U.S. moves closer to establishing domestic supply of Mo-99 for nuclear imaging

SNMMI unveils Image of the Year